Clinical data | |
---|---|
Other names | N-(1-Oxohexyl)-l-tyrosyl-N-(6-amino-6-oxohexyl)-l-isoleucinamide |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C27H44N4O5 |
Molar mass | 504.672 g·mol−1 |
3D model ( JSmol) | |
| |
|
Dihexa (developmental code name PNB-0408), also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is an oligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met. The compound has been found to potently improve cognitive function in animal models of Alzheimer's disease-like mental impairment. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In an assay of neurotrophic activity, Dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor. [11]
According to a patent, "Short duration safety studies with Dihexa have uncovered no apparent toxicity. Of particular note is a lack of neoplastic induction[ citation needed], since c-Met is recognized as an oncogene. This is unsurprising since oncogenesis requires multiple mutations including both oncogene induction and tumor suppressor attenuation." [12][ citation needed]
Dihexa was developed by Joseph Harding and his team at Washington State University. [13] Later developments were done under " M3 Biotechnology", a company founded to commercialise Dihexa. [14]
Clinical data | |
---|---|
Other names | N-(1-Oxohexyl)-l-tyrosyl-N-(6-amino-6-oxohexyl)-l-isoleucinamide |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C27H44N4O5 |
Molar mass | 504.672 g·mol−1 |
3D model ( JSmol) | |
| |
|
Dihexa (developmental code name PNB-0408), also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is an oligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met. The compound has been found to potently improve cognitive function in animal models of Alzheimer's disease-like mental impairment. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In an assay of neurotrophic activity, Dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor. [11]
According to a patent, "Short duration safety studies with Dihexa have uncovered no apparent toxicity. Of particular note is a lack of neoplastic induction[ citation needed], since c-Met is recognized as an oncogene. This is unsurprising since oncogenesis requires multiple mutations including both oncogene induction and tumor suppressor attenuation." [12][ citation needed]
Dihexa was developed by Joseph Harding and his team at Washington State University. [13] Later developments were done under " M3 Biotechnology", a company founded to commercialise Dihexa. [14]